Ibrutinib and Bacteraemia - a phase IV clinical study of FDA data

Summary:

Bacteraemia is reported as a side effect among people who take Ibrutinib (ibrutinib), especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months also take Lenalidomide, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Bacteraemia when taking Ibrutinib. It is created by eHealthMe based on reports of 13,522 people who have side effects when taking Ibrutinib from the FDA, and is updated regularly.

What is Ibrutinib?

Ibrutinib has active ingredients of ibrutinib. eHealthMe is studying from 13,529 Ibrutinib users. Check the latest studies of Ibrutinib.

What is Bacteraemia?

Bacteraemia (presence of bacteria in the blood) is found to be associated with 1,023 drugs and 1,517 conditions by eHealthMe. Check the latest studies of Bacteraemia.

On Jul, 11, 2026

13,522 people reported to have side effects when taking Ibrutinib.
Among them, 50 people (0.37%) have Bacteraemia.

Among these 50 people:

How long have people been on Ibrutinib when they have Bacteraemia? *

What is the gender of people who have Bacteraemia when taking Ibrutinib? *

female: 42.22 %
male: 57.78 %

What is the age of people who have Bacteraemia when taking Ibrutinib? *

What are other drugs people take besides Ibrutinib? *

What are other side effects people have besides Bacteraemia? *

Pneumonia: 14 people, 28.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 7 people, 14.00%
Soft Tissue Infection: 6 people, 12.00%
Central Nervous System Infection (infection of brain or spinal cord): 6 people, 12.00%
Drug Ineffective: 6 people, 12.00%
Infection: 5 people, 10.00%
Rashes (redness): 5 people, 10.00%
Pleural Effusion (water on the lungs): 4 people, 8.00%
Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream): 4 people, 8.00%
Urinary Tract Infection: 4 people, 8.00%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 21 people, 42.00%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 11 people, 22.00%
Burkitt Lymphoma (cancer of the lymphatic system): 8 people, 16.00%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 8 people, 16.00%
High Blood Pressure: 4 people, 8.00%
Peripheral T-Cell Lymphoma Unspecified (peripheral t-cell cancer unspecified): 3 people, 6.00%
Diabetes: 3 people, 6.00%
Nausea (feeling of having an urge to vomit): 2 people, 4.00%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 4.00%
Central Nervous System Lymphoma (cancer of central nervous system forms in lymph tissue): 2 people, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrutinib and have Bacteraemia?

- Check whether Bacteraemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibrutinib:

Ibrutinib (13,529 reports)

Bacteraemia treatments and more:

Bacteraemia (15,996 reports)

Browse all side effects of Ibrutinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bacteraemia:

Bacteraemia (1,023 drugs)

Browse all the conditions that are associated with Bacteraemia:

Bacteraemia (1,517 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Ibrutinib) and Ibrutinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.